Editas CEO sells shares to cover tax withholding

Editas Medicine CEO O'Neill Gilmore Neil reported an automatic tax-related share sale.

Rhea-AI Filing Summary

Editas Medicine CEO O'Neill Gilmore Neil reported an automatic tax-related share sale. On March 3, 2026, he sold 5,394 shares of Editas Medicine common stock in open-market transactions at a weighted average price of $2.0197 per share. The footnotes explain the sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022 to cover tax withholding on restricted stock units that vested on March 2, 2026, and did not represent a discretionary trade. Following this transaction, he held 263,693 shares of common stock directly.

Insider Trade Summary

Net Seller: 5,394 shares

Net Sell 1 txn

Insider O'Neill Gilmore Neil

Role CEO

Sold 5,394 shs ($11K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,394	$2.0197	$11K

Holdings After Transaction: Common Stock — 263,693 shares (Direct)

Footnotes (2)

1. F1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
2. F2. This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Editas Medicine (EDIT) CEO report in this Form 4 filing?

Editas Medicine CEO O'Neill Gilmore Neil reported selling 5,394 shares of common stock. The shares were sold in open-market transactions to cover tax withholding obligations arising from restricted stock units that vested on March 2, 2026, under a pre-established automatic sales instruction plan.

How many Editas Medicine shares did the CEO sell and at what price?

The CEO sold 5,394 shares of Editas Medicine common stock at a weighted average price of $2.0197 per share. The transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204, with the reported figure representing the weighted average sale price.

Was the Editas Medicine CEO’s Form 4 share sale a discretionary trade?

The sale was not a discretionary trade by the CEO. Footnotes state it was carried out under a durable automatic sales instruction plan adopted on April 13, 2022, specifically to meet tax withholding obligations from restricted stock units that vested on March 2, 2026.

Why did the Editas Medicine CEO sell shares in this Form 4 transaction?

The CEO sold shares to satisfy tax withholding obligations tied to vesting restricted stock units. The filing explains that the transaction represented the sale of issuer shares necessary to meet tax withholding from RSUs that vested on March 2, 2026, under a pre-arranged automatic sales plan.

How many Editas Medicine shares does the CEO hold after this reported sale?

After the reported sale, the CEO directly held 263,693 shares of Editas Medicine common stock. This post-transaction ownership figure is explicitly stated in the filing and reflects his direct holdings following the 5,394-share tax-related sale on March 3, 2026.

What trading range applied to the Editas CEO’s reported share sale?

The transaction was executed in multiple trades within a narrow price range. According to the footnotes, the individual sale prices ranged from $2.0050 to $2.0204 per share, and the Form 4 reports a weighted average sale price of $2.0197 per share for the 5,394 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Neill Gilmore Neil

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY ST.

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		5,394	D	$2.0197(2)	263,693	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Gilmore O'Neill	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.